| OVs component | Target of CAR | Signaling domain of CAR | Cancer type | Quantity | Result | Ref |
| AdC68-TMC-Tcd19 | CD19 | CD3ζ + 4-1BB + CD28 | Hepatic | 4 × 106 CAR T and 8 × 106 OVs | Tumor decrease and outlive | [123] |
| rAd.sT | meso | CD3ζ + 4-1BB + CD28 | Breast | 1 × 107 meso CAR and 2.5 × 1010 OVs | Weight, volume and metastasis of tumor decrease | [124] |
| CAdTrio | HER2 | CD3ζ + CD28 | Skin | 1 × 106 CAR and 108 OVs | Tumor volume decrease and better condition | [125] |
| mCD19VV | CD19 | CD3ζ + CD28 | Melano-ma skin | 1 × 107 CAR and 108 OVs | Tumor volume decrease | [123] |
| OV19t | CD19 | CD3ζ + 4-1BB | Breast | 107 OVs and 5 × 106 CAR T | Decrease of tumor volume | [126] |
| IL-2 | meso | CD3ζ + 4-1BB | PDAC | 1 × 109 Onc.Ad and 5 × 106 CAR T | Tumor growth and metastasis reduce | [127] |
| Onc.Ad-EGFR BiTE | FR-a | CD3ζ + ICOS | PDAC or CRC | 1 × 107 CAR and 109 OVs | Reduce tumor growth | [128] |
| VV. CXCL-11 | meso | CD3ζ + 4-1BB | Lung | 108 OVs and 1 × 107 CAR | Tumor volume consumes | [129] |
| CAdVEC-aPDL1 | HER2 | CD3ζ + CD28 | Skin and Prostate | 1 × 106 CAR and 107 OVs | Suppress of tumor volume | [130] |
| aPDL1 | HER2 | CD3ζ + CD28 | Head and neck skin cancer | 1 × 106 CAR and 108 OVs | Tumor metastasis and growth consumes | [131] |
| IL-15 | Ganglio-side GD2 | CD28 + OX40 | Neurobl-stoma | 1 × 107 CAR and 109 OVs | Tumor growth decrease | [132] |
| EphA2-TEA-VV | HER2 | CD3ζ + CD28 | Lung | 1 × 107 CAR and 109 OVs | Survival and tumor growth reduce | [122] |